



A Retrospective Case Series of and Proposed Framework for Palliative Care Discussions in Patients with Multiple Systems Atrophy



A.M. Dayal, M.E. Jenkins, M.S. Jog, K. Kimpinski, P. MacDonald, T.E. Gofton
London Health Sciences Centre, Department of Clinical Neurological Sciences
Western University, London, Ontario, Canada

Background

- Multiple Systems Atrophy (MSA) is a rare neurodegenerative disease of the central and autonomic nervous system, with a mean survival of 7-10 years³.
- It has a prevalence of 5/100,000².
 - There is no cure for MSA and treatment is purely symptomatic.
- Stridor is a major complication that develops in 30% of cases⁴.
- Case reports indicate that untreated stridor is a marker of short survival and may lead to obstructive sleep apnea, acute laryngeal obstruction and death.
- Tracheostomy is the optimal treatment for stridor although required in a minority of cases.
- Respiratory failure arising from stridor can present acutely, and may require a tracheostomy as a life-supportive measure.
 - Important to have early and deliberate advance care planning and goals of care discussions.
 - Including a realistic assessment of patients quality of life and value of tracheostomy as supportive measure.
- Little evidence to guide physicians in their approach to care in MSA¹.

Objectives

- To evaluate advanced care planning and current practices in palliative care in MSA in order to identify opportunities to improve quality of care.
- To propose a framework for advance care planning and palliative care discussions in MSA.

Methods

- Study:**
 - A retrospective, non-concurrent cohort study exploring the symptom burden of patients living with MSA and the palliative care discussions that take place during the disease trajectory.
- Inclusion criteria:**
 - Adult patients with a clinical diagnosis of MSA, meeting the criteria for a clinical diagnosis of probable MSA (Gilman et al. 2008).
 - Known to inpatient or outpatient neurology services at London Health Sciences Centre (LHSC) between January 2004 and January 2014.
- Exclusion criteria:**
 - Patients with Parkinsonian syndromes of uncertain etiology or with a diagnosis of an alternate Parkinson's plus syndrome.
- Data collection:**
 - Patients were identified from the clinical practices of all movement disorder and autonomic disorder specialists at LHSC.
 - Electronic medical records and paper charts for all visits to LHSC were reviewed.
- Data Analysis:**
 - Data on common clinical symptoms were collected.
 - Content of palliative care discussions documented in the patient's medical record was recorded:
 - diagnosis, symptom management, prognosis, goals of care, comfort measures and decision making regarding tracheostomy.
 - cases with no evidence of documented discussions in the medical record "unknown" was used.
- Sources of bias:**
 - In order to reduce bias, only data documented in the patients' charts were included in the analysis.
- Statistical analysis:**
 - Due to the small number of patients included and the descriptive nature of the data, detailed statistical analysis was not performed.

Results

Table 1 Characteristics of patients with Multiple Systems Atrophy seen in outpatient neurology clinics or admitted under inpatient services at London Health Sciences Centre from January 2004 to January 2014

	Total MSA (%)	Those with Stridor		
		Total	No Tracheostomy	Tracheostomy
All Patients	22 (100%)	6 (27% of 22)	3 (50% of 6)	3 (50% of 6)
Female	12 (55% of 22)	4 (18% of 22)	2 (40% of 5)	2 (40% of 5)
Male	10 (45% of 22)	2 (9% of 22)	1 (20% of 5)	1 (20% of 5)
Age at diagnoses	62.1 ± 8.7	60.8 ± 7.2	56 ± 5.3	65.6 ± 5.7
Age	65.5 ± 7.9	64 ± 6.4	59.6 ± 4.9	68.3 ± 4.9
Duration of disease (mean in years)	6.8 ± 3.6	6.4 ± 4.4	7.0 ± 6.1	5.5 ± 0.7
Deceased	6 (27% of 22)	3 (50% of 6)	1 (20% of 5)	1 (20% of 5)

Figure 1 – Symptom Burden of Patients Living with MSA




Figure 2: Types of Palliative care discussions in MSA




Table 2 End of life discussions: The focus and timing of end of life discussions

	MSA Patients (%) N=22	Those with Stridor		Unknown
		Tracheostomy	No Tracheostomy	
Respite care discussion	06 (27%)	2 (100%)	unknown	16 (72%)
Palliative care discussion	16 (72%)	2 (100%)	unknown	06 (27%)
Appointed health care proxy	07 (32%)	2 (100%)	unknown	15 (68%)
Do-not-resuscitate order	07 (32%)	2 (100%)	unknown	14 (64%)
Documented Full Code	01 (5%)	unknown	unknown	14 (64%)


Table 3 End of life discussions: Deceased patient demographics

	MSA Patients (%) N=22	Those with Stridor		Unknown
		Tracheostomy	No Tracheostomy	
Total deceased	6 (27%)	2 (9%)	1 (4%)	0
Time from admission to death (days)	hours – 28d ± 18.2d	24.5d ± 30.4d	unknown	1 (16%)
Time from palliative discussion to death (days)	hours – 9d ± 9.9d	hours/16 days	unknown	1 (16%)
Documented DNR in place prior to death	2 (33%)	0	unknown	1 (16%)
Time from DNR to death	hours/16 days	hours/16 days	unknown	2 (33%)
Decision for DNR made in emergency/intensive care unit prior to death	3 (50%)	2 (100%)	unknown	1 (16%)

Conclusion

- Physicians effectively engaged patients in discussions regarding diagnosis, symptom management and prognosis in MSA, but they were less thorough regarding discussions for DNAR and end of life plans.
- End of life discussions were initiated very late in the disease trajectory.
- Timing was variable for those who underwent tracheostomy.
- Limited documentation outlining the content of all palliative care discussions in the medical record.
- No standard approach to advanced care planning and palliative care discussions in patients living with MSA.
- Despite these unknowns, early discussions will allow people with MSA to make treatment decisions that align with their goals of care prior to an emergency situation.
- Advanced care planning has been shown to improve outcomes with respect to the dying process¹⁴.
- A systematic approach to palliative care in MSA would enable patients and substitute decision makers to make informed health care decisions, throughout the disease trajectory.

Proposed Framework



References

- Werning GK, Geser F, Poewe W (2005) Therapeutic strategies in multiple system atrophy. *Movement Disorders* 20(12): S67-S76.
- Bradley WG, Daroff RB, Ferlicel GM, Janovic J. 2012. *Neurology in Clinical Practice: Parkinsonian syndromes*. Philadelphia: Elsevier. 1777.
- Silber MH, Levine S (2000) Stridor and death in multiple system atrophy. *Movement Disorders* 15(4): 699-704.
- Yamaguchi M, Arai K, Asahin M, Hattori T (2003) Laryngeal stridor in multiple system atrophy. *Eur Neurol* 49: 154-159.
- Hardy J (2008) Multiple system atrophy: pathophysiology, treatment and nursing care. *Nursing Standard* 22: 50-56.
- Tuck KK, Brod L, Nutt J, Fromme E. 2013: Preferences of patients with Parkinson's Disease for communication about advanced care planning. *American Journal of Hospice and Palliative Medicine* 00(0): 1-10.
- Peerenboom K and Coyle N. 2012: Facilitating goals-of-care discussions for patients with life-limiting disease – communication strategies for nurses. *Journal of Hospice and Palliative Nursing* 14(4): 251-256.
- Chahine LM, Malik B, Davis M. 2008: Palliative care needs of patients with neurologic or neurosurgical conditions. *Eur Jour Neurol* 15: 1265-1272.
- Davson S and Li Kristjansson 2003: Mapping the journey: Family carers' perceptions of issues related to end-stage care of individuals with muscular dystrophy or motor neuron disease. *Journal of Palliative Care* 19(1): 36-42.
- Notin MT, Kub J, Hughes MT et al. 2008: Family health care decision making and self-efficacy with patients with ALS at the end of life. *Palliat Support Care* 6(3): 273-280.
- Almack K, Cox K, Moghaddam N, Seymour J. 2012: After you: conversations between patients and healthcare professionals in planning for end of life care. *BMC Palliative Care* 11(15):1-10.
- Cox K, Moghaddam N, Almack K, Pollock K, Seymour J. 2011: Is it recorded in the notes? Documentation of end-of-life care and preferred place to die discussions in the final weeks of life. *BMC Palliative Care* 10(18): 1-9.
- Gofton T, Jog M and V Schultz 2009: A palliative approach to neurological care – a literature review. *CJNS* 36(3):296-302.

Disclosures

The authors; A.M. Dayal, M.E. Jenkins, M.S. Jog, K. Kimpinski, P. MacDonald, and T.E. Gofton, have no disclosures or conflicts of interest to declare.